Latest News

child with inflammatory bowel disease | Image credit: zinkevych -
Real-World Study: Nonmedical Switch to Infliximab Biosimilar Is Safe, Effective in Pediatric Patients With IBD

June 12th 2024

A real-world study of children and young adults with inflammatory bowel disease (IBD) switched from the infliximab reference product to a biosimilar concluded effectiveness was maintained over 12 months based on stable remission rates and biochemical markers.

doctor and patient | Image credit: sebra -
Switching Patients With IBD to Infliximab, Adalimumab Biosimilars Did Not Impact Efficacy

June 8th 2024

Biosimilars Check-In banner
Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships

June 6th 2024

syringes | Image credit: Napat -
New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching

May 28th 2024

Eye on Pharma banner
Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars

May 27th 2024

Video Interviews
CFB podcast banner
CFB podcast banner
CFB podcast banner
CfB podcast banner
CFB podcast banner

More News

© 2024 MJH Life Sciences

All rights reserved.